Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Abattis Rebrands as a Downstream Solutions Provider for the Cannabis Market


Posted on: 06 Mar 18

VANCOUVER, British Columbia, March 06, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE:ATT) (OTC:ATTBF) is pleased to announce it has officially rebranded itself as a one-stop provider of downstream cannabis solutions for licensed producers (“LPs”) and manufacturers of cannabinoid-containing products. The Company’s new focus on downstream solutions reflects several of its recent acquisitions and the success of its fully integrated services offerings. These offerings now include biomass production, federally-licensed research and development and analytical services, regulatory services, logistics support for the manufacture, sale, distribution and marketing of cannabinoid-containing finished products and cannabinoid delivery products and blockchain-based peer-to-peer payment technologies.

"We intend for the rebranding to consolidate our recent acquisitions and pave the way for exciting new partnerships in the future," stated Rob Abenante, President and CEO of Abattis. “For example, our recent acquisition of Gabriola Green Farms will round out our supply chain, providing us and our partners with integrated services spanning from biomass production to the manufacture of high-end cannabis extracts,” added Mr. Abenante. 

“While continuing to develop our in-house nanotechnology delivery platforms, we hope to support our partners in multiple aspects of their businesses, from helping them increase manufacturing and distribution capacity to, in the case of established brands, guiding their entry into the cannabis space. Our suite of integrated services will also address our partners’ future needs, providing comfort that they will be able to adapt once legalization arrives this summer,” further stated Mr. Abenante.

"Abattis’s wide range of downstream services allows it to add value and ensure regulatory compliance for its partners, while assisting the development of their functional foods and beverages, cosmetics, veterinary and over-the-counter health products, to name a few,” added Dr. David Galvez, Senior Science Advisor at Abattis.

Recent Developments

Gabriola Green Farms                                                    

On March 2, 2018, the Company announced that it had acquired a 90% ownership interest in Gabriola Green Farms Inc. (“Gabriola Green Farms”), an LP applicant located on Gabriola Island, one of the gulf islands located in the Strait of Georgia off the coast of British Columbia. 

By becoming the majority-shareholder of Gabriola Green Farms, Abattis intends to secure access to cannabis biomass for its extraction and manufacturing activities with respect oils, resins and isolates. These added value products could be used as stand-alone applications or as active ingredients for current and new finished products. 

Green Tree Therapeutics  

On January 25, 2018, the Company announced that it had acquired Green Tree Therapeutics Corporation (“Green Tree”), the owner of a successful brand of vaporizers sold in more than 130 medical and recreational stores across North America. Green Tree’s products will soon be available through Abattis’s wholly-owned subsidiary Vergence Naturals Ltd. Abattis’s acquisition of Green Tree will allow the Company to directly pair and distribute cannabinoid-containing oils and extracts with Green Tree’s line of vaporizers. 

CannaNUMUS  

On February 8, 2018, the Company announced that it had acquired a 49% stake in CannaNUMUS Blockchain Inc. (“CannaNUMUS”). Abattis’s investment in CannaNUMUS has already reached two significant milestones by securing an investment agreement with Active Health Products Ltd. and acquiring a 10% stake in Gabriola Green Farms. 

With this acquisition, Abattis has gained the ability to offer blockchain-based peer-to-peer payment services to cannabis merchants, a market segment not been currently served by traditional financial institutions. Abattis believes that its investment in CannaNUMUS will appreciate significantly in value as CannaNUMUS gets closer to an ICO (Initial Coin Offering) and enters into agreements with other LPs and late stage LP applicants.

Collaboration with UBC on Nanotechnology

On February 12, 2018 the Company announced the sponsorship of a research study in partnership with Mitacs to explore the development of nanoemulsified and liposomal platforms for transmucosal delivery of cannabinoid-rich hemp oil. The research and development work is being led by scientists from Abattis and the Faculty of Land and Food Systems at the University of British Columbia (“UBC”).

Through this collaboration, Abattis hopes to develop a proprietary technology that could be applied to the manufacture and distribution of high-end nanoemulsified cannabinoid-rich oils with enhanced absorption and bioavailability. These oils could be used to create safe and stable premium foods and beverages and could be used in cosmetics and veterinary applications. 

About Abattis Bioceuticals Corp. 

Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com

ON BEHALF OF THE BOARD OF
ABATTIS BIOCEUTICALS CORP.,

"Rob Abenante"
Robert Abenante, President & CEO

For more information, please visit the Company's website at: www.abattis.com or www.northernvinelabs.com

For inquiries, please contact the Company at (604) 674-8232 or at news@abattis.com.

This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", “intends”, "should", "believe" and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include statements regarding: the Company’s intention for the rebranding to consolidate its recent acquisitions and pave the way for exciting new partnerships in the future; the Company’s acquisition of Gabriola Green Farms rounding out its supply chain and providing Abattis and its partners with integrated services spanning from biomass production to the manufacture of high-end cannabis extracts; the Company’s hope to support its partners in multiple aspects of their businesses, from helping them increase manufacturing and distribution capacity to, in the case of established brands, guiding their entry into the cannabis space; the Company’s suite of integrated services addressing its partners’ future needs, providing comfort that they will be able to adapt once legalization arrives this summer; Abattis’s intention to secure access to cannabis biomass for its extraction and manufacturing activities with respect oils, resins and isolates; Gabriola Green Farms’s products’ potential use as stand-alone applications or as active ingredients for current and new finished products; Abattis’s belief that its investment in CannaNUMUS will appreciate significantly in value as CannaNUMUS gets closer to an ICO (Initial Coin Offering) and enters into agreements with other LPs and late stage LP applicants; Abattis’s hope to develop a proprietary technology that could be applied to the manufacture and distribution of high-end nanoemulsified cannabinoid-rich oils with enhanced absorption and bioavailability and that such oils could be used to create safe and stable premium foods and beverages and could be used in cosmetics and veterinary applications. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties, including: that the rebranding will not consolidate the Company’s recent acquisitions or pave the way for exciting new partnerships in the future; that the Company’s acquisition of Gabriola Green Farms will not round out the Company’s supply chain or provide it or its partners with integrated services spanning from biomass production to the manufacture of high-end cannabis extracts; that the Company will not be able to support its partners in multiple aspects of their businesses; that the Company’s suite of integrated services will not address its  partners’ future needs or will not provide comfort that such partners will be able to adapt once legalization arrives this summer; that Abattis will not be able to secure access to cannabis biomass for its extraction and manufacturing activities with respect oils, resins and isolates; that Gabriola Green Farms’s products will not be useful as stand-alone applications or as active ingredients for current or new finished products; that Abattis’s investment in CannaNUMUS will not appreciate as expected or at all, or that CannaNUMUS will not complete an ICO (Initial Coin Offering) or enter into agreements with other LPs or late stage LP applicants; that Abattis will not develop a proprietary technology that could be applied to the manufacture and distribution of high-end nanoemulsified cannabinoid-rich oils with enhanced absorption and bioavailability or that such oils may not be used to create safe and stable premium foods and beverages or may not be used in cosmetics and veterinary applications; that the Company will not be able to execute its proposed business plan in the time required or at all due to regulatory, financial or other issues; that the Company’s competitors may develop competing technologies; changes in regulatory requirements; and other factors beyond the Company’s control. Additional risk factors are included in the Company's Management's Discussion and Analysis, available under the Company's profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where because of new information, future events or results, or otherwise, except as required by applicable securities laws.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

GlobeNewswire
globenewswire.com

Last updated on: 06/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.